Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

10 Sep 2019

Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered NSCLC and thyroid cancer patients who may be suitable for Lilly's RET inhibitor.

Thermo Fisher Scientific has announced an agreement with Eli Lilly for the development of a companion diagnostic that will use the FDA-approved, next-generation sequencing-based Oncomine Dx Target Test to identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients who may be treated with Lilly's investigational therapy, LOXO-292. Specifically, the test would be used with patients whose tumors harbor a rearranged during transfection (RET) alteration. RET variants are found in about 2% of NSCLC, about 60% of medullary thyroid cancer (MTC) and up to approximately 20% of other thyroid cancers.

Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

LOXO-292 is a highly selective and potent oral RET inhibitor being studied by Lilly in a Phase I/II clinical trial for the treatment of advanced cancers that harbor activating alterations of the RET kinase. Changes in the RET kinase, including fusions and mutations, can cause uncontrolled cell growth leading to tumor development. Cancers driven by such alterations are mostly dependent on this singularly activated pathway, making them highly susceptible to small molecule inhibitors.

"One of the biggest barriers to realizing the full power of precision medicine in oncology is having access to high-quality testing, such as next-generation sequencing-based tests, that identify a broad range of clinically actionable alterations, can be performed locally and allow treating institutions to participate in this important step in the evolving treatment paradigm," said Anne White, president of Lilly Oncology. "With this agreement, we believe that more patients will gain access to high-quality tumor profiling, identifying those with RET alterations potentially suitable for LOXO-292 therapy, in addition to other alterations suitable for treatment with other therapies."

Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific said: "We are pleased to enter into this agreement with Lilly and leverage our Oncomine platform as a means to quickly identify cancer patients who may benefit from this breakthrough therapy, even in cases of limited sample availability. We are committed to working with our global pharmaceutical partners to help bring forth next-generation sequencing-based companion diagnostics and best-in-class therapies that can have a profound impact on treating cancer patients."

Under the terms of the agreement, Thermo Fisher will retain the rights to commercialize the test in all markets, including the US, Europe and Japan. Once validation is complete, Thermo Fisher will submit a supplemental premarket approval (sPMA) application to the FDA to broaden the clinical claims of its Oncomine Dx Target Test.

The NGS test, which received FDA approval in 2017, simultaneously screens tumor samples for multiple gene variants associated with NSCLC, a subset of which are utilized to identify patients who may be eligible for several approved targeted therapies. It is covered in the US by the Centers for Medicare & Medicaid Services and a majority of the largest commercial US health plans. Oncomine Dx Target Test is also approved for reimbursement by the Japan Ministry of Health, Labor and Welfare (MHLW).

Read More

Related news

New microbial air sampler addresses continuous monitoring

New microbial air sampler addresses continuous monitoring

14 Nov 2019

The device supports the new EU GMP Annex 1 requirements.

Read more 
GVK Bio continues to see growth tailwinds for 2020 thanks to a ‘crescendo of factors’

GVK Bio continues to see growth tailwinds for 2020 thanks to a ‘crescendo of factors’

13 Nov 2019

China-US trade challenges has led to de-risking by pharma companies.

Read more 
Winners of the 16th Pharma Awards

Winners of the 16th Pharma Awards

11 Nov 2019

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

Read more 
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

8 Nov 2019

But personalized medicines will require new logistics and manufacturing systems.

Read more 
SGH Healthcaring unveils its new asthma spacer device

SGH Healthcaring unveils its new asthma spacer device

8 Nov 2019

Zephyr's revolutionary new design improves drug administration and simplifies treatment delivery for better observance.

Read more 
Recipharm expands Indian injectable dosage form capabilities

Recipharm expands Indian injectable dosage form capabilities

7 Nov 2019

Partnership will combine capabilities and expertise in Europe and India to build a new facility dedicated to injectable formulations to supply demand from Europe and overseas territories.

Read more 
Aptar acquires a leader in drug delivery training devices and patient onboarding

Aptar acquires a leader in drug delivery training devices and patient onboarding

6 Nov 2019

Acquisition reflects movement of treatments being administered by patients at home rather than by healthcare providers.

Read more 
Europe predicted to surpass the US in biologic manufacturing capacity by 2023

Europe predicted to surpass the US in biologic manufacturing capacity by 2023

6 Nov 2019

Demand for biological manufacturing is growing faster than capacity growth.

Read more 
SP acquires Spain based global provider of complete sterile filling lines

SP acquires Spain based global provider of complete sterile filling lines

5 Nov 2019

Company's strategic move reflects its expectation of short-run aseptic liquid filling to continue to drive pharmaceutical growth.

Read more 
Legacy recruits heavily to meet growing steriles demand

Legacy recruits heavily to meet growing steriles demand

5 Nov 2019

Company to reach 250 employees by year end to meet growing drug product manufacturing demand.

Read more